Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Liedtke · SciRah

Researcher profile · Semantic Scholar

C. Liedtke

Share profile

C. Liedtke — researcher profile on SciRah

h-index: 43
Works: 233
Citations: 13K

Most-cited papers

Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
C. Denkert, C. Liedtke, A. Tutt, G. von Minckwitz
2017The Lancet717 citations
Semantic Scholar
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Miguel Martín, F. Holmes, B. Ejlertsen, S. Delaloge +496 more
2017The Lancet Oncology512 citations
Semantic Scholar
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
O. Gluz, U. Nitz, M. Christgen, R. Kates +17 more
2016Journal of Clinical Oncology286 citations
Semantic Scholar
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
U. Nitz, O. Gluz, M. Christgen, R. Kates +17 more
2017Breast Cancer Research and Treatment183 citations Open access
Semantic Scholar
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
U. Nitz, O. Gluz, M. Christgen, E. Grischke +17 more
2017Annals of Oncology121 citations Open access
Semantic Scholar
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
U. Nitz, O. Gluz, M. Clemens, W. Malter +16 more
2019Journal of Clinical Oncology116 citations
Semantic Scholar
Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.
Miguel Martín, S. Loibl, G. von Minckwitz, S. Morales +15 more
2015Journal of Clinical Oncology116 citations Open access
Semantic Scholar
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results
O. Gluz, U. Nitz, C. Liedtke, M. Christgen +21 more
2018Journal of the National Cancer Institute113 citations
Semantic Scholar
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
P. Fasching, S. Loibl, Chun-Ling Hu, S. Hart +23 more
2018Journal of Clinical Oncology100 citations Open access
Semantic Scholar
Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.
J. Lindner, S. Loibl, C. Denkert, B. Ataseven +17 more
2015Annals of Oncology81 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2016
C. Liedtke, M. Thill
2016Breast Care79 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2018
C. Liedtke, C. Jackisch, M. Thill, C. Thomssen +2 more
2018Breast Care68 citations Open access
Semantic Scholar
Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy - Results from the multi-center SENTINA trial.
L. Schwentner, G. Helms, V. Nekljudova, B. Ataseven +16 more
2017Breast65 citations Open access
Semantic Scholar
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
C. Liedtke, C. Mazouni, K. Hess, F. André +9 more
2023Journal of Clinical Oncology62 citations
Semantic Scholar
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
C. Jackisch, N. Harbeck, J. Huober, G. von Minckwitz +21 more
2015Breast Care59 citations Open access
Semantic Scholar
Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age
J. Radosa, A. Eaton, M. Stempel, Amrin Khander +6 more
2016Annals of Surgical Oncology57 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2017
M. Thill, C. Liedtke, E. Solomayer, V. Müller +2 more
2017Breast Care50 citations Open access
Semantic Scholar
Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
P. Fasching, A. Hartkopf, P. Gass, L. Häberle +31 more
2018Breast Cancer Research and Treatment46 citations
Semantic Scholar
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel.
U. Nitz, O. Gluz, M. Christgen, E. Grischke +17 more
201738 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2017
C. Liedtke, M. Thill, C. Jackisch, C. Thomssen +2 more
2017Breast Care34 citations Open access
Semantic Scholar
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
A. Hein, D. Lambrechts, G. von Minckwitz, L. Häberle +30 more
2015International Journal of Cancer33 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015
C. Liedtke, M. Thill, V. Hanf, F. Schütz
2015Breast Care32 citations Open access
Semantic Scholar
Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts
C. Liedtke, H. Kolberg
2016Breast Care31 citations Open access
Semantic Scholar
New treatment strategies for patients with triple-negative breast cancer
C. Liedtke, A. Rody
2015Current Opinion in Obstetrics and Gynecology31 citations
Semantic Scholar
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus Erstbehandlung von Patientinnen mit primärem Mammakarzinom: Evidenz, Kontroversen, Konsens
M. Untch, J. Huober, C. Jackisch, A. Schneeweiss +17 more
2017Geburtshilfe und Frauenheilkunde27 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2018
M. Thill, C. Liedtke, V. Müller, W. Janni +1 more
2018Breast Care26 citations Open access
Semantic Scholar
Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus
M. Untch, N. Harbeck, J. Huober, G. von Minckwitz +21 more
2015Geburtshilfe und Frauenheilkunde25 citations Open access
Semantic Scholar
Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer
N. Harbeck, O. Gluz, M. Christgen, M. Braun +16 more
201621 citations
Semantic Scholar
BRCA1‐like profile predicts benefit of tandem high dose epirubicin‐cyclophospamide‐thiotepa in high risk breast cancer patients randomized in the WSG‐AM01 trial
P. Schouten, O. Gluz, N. Harbeck, S. Mohrmann +12 more
2016International Journal of Cancer20 citations Open access
Semantic Scholar
Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.
N. Harbeck, O. Gluz, M. Clemens, W. Malter +16 more
201719 citations
Semantic Scholar
Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.
N. Harbeck, O. Gluz, M. Christgen, M. Braun +16 more
201518 citations
Semantic Scholar
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
N. Harbeck, R. von Schumann, R. Kates, M. Braun +16 more
2021Cancers15 citations Open access
Semantic Scholar
Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.
H. Kolberg, G. Loevey, L. Akpolat-Basci, M. Stephanou +5 more
2017Reviews on recent clinical trials15 citations Open access
Semantic Scholar
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
O. Gluz, C. Liedtke, J. Huober, H. Peyro-saint-paul +16 more
2016Annals of Oncology15 citations Open access
Semantic Scholar
Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer
G. Schmidt, C. Gerlinger, I. Juhasz-Böss, E. Stickeler +11 more
2016Journal of Cancer Research and Clinical Oncology15 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2016
M. Thill, C. Liedtke
2016Breast Care14 citations Open access
Semantic Scholar
Prospective WSG phase III PlanB trial: Clinical outcome at 5 year follow up and impact of 21 Gene Recurrence Score result, central/local-pathological review of grade, ER, PR and Ki67 in HR+/HER2-high risk node-negative and -positive breast cancer
O. Gluz, U. Nitz, M. Christgen, R. Kates +16 more
201614 citations
Semantic Scholar
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
R. Erber, O. Gluz, N. Brünner, H. Kreipe +16 more
2015Breast Cancer Research and Treatment14 citations
Semantic Scholar
Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer
M. Braun, O. Gluz, U. Nitz, M. Christgen +14 more
201613 citations
Semantic Scholar
Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
K. Bräutigam, K. Mitzlaff, L. Uebel, F. Köster +5 more
2016Anticancer Research13 citations
Semantic Scholar
Initial Treatment of Patients with Primary Breast Cancer : Evidence , Controversies , Consensus Spectrum of Opinion of German Specialists at the 15 th International
M. Untch, J. Huober, C. Jackisch, A. Schneeweiss +17 more
201712 citations
Semantic Scholar
Neoadjuvant Therapy for Patients with Triple Negative Breast Cancer (TNBC).
C. Liedtke, A. Rody
2017Reviews on recent clinical trials12 citations
Semantic Scholar
Abstract GS5-06: No survival benefit of chemotherapy escalation in patients with pCR and “high-immune” triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial
O. Gluz, U. Nitz, C. Liedtke, A. Prat +19 more
2019General Session Abstracts11 citations
Semantic Scholar
Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab {+/-} weekly paclitaxel in HER2+/HR- early breast cancer (EBC).
U. Nitz, O. Gluz, M. Christgen, E. Grischke +15 more
201611 citations
Semantic Scholar
Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years
H. Kolberg, L. Akpolat-Basci, M. Stephanou, B. Aktas +2 more
2016Breast Care11 citations Open access
Semantic Scholar
Abstract S5-06: BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study
P. Fasching, S. Loibl, H. Eidtmann, H. Tesch +20 more
201611 citations
Semantic Scholar
Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer
H. Kolberg, G. Lövey, L. Akpolat-Basci, M. Stephanou +6 more
2017Breast Care10 citations Open access
Semantic Scholar
Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial
O. Gluz, U. Nitz, C. Liedtke, M. Christgen +21 more
201610 citations
Semantic Scholar
Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.
O. Gluz, U. Nitz, M. Christgen, R. Kates +16 more
20169 citations
Semantic Scholar
Lymph Nodes in Breast Cancer - What Can We Learn from Translational Research
F. Peintinger, R. Reitsamer, M. Smidt, T. Kühn +1 more
2018Breast Care8 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. Harbeck×21
Invite
N. Harbeck — researcher profile on SciRah
O. Gluz×19
Invite
O. Gluz — researcher profile on SciRah
R. Kates×17
Invite
R. Kates — researcher profile on SciRah
U. Nitz×16
Invite
U. Nitz — researcher profile on SciRah

×16

Invite

R. Wuerstlein — researcher profile on SciRah

M. Christgen×15

Invite

M. Christgen — researcher profile on SciRah

Invite

B. Aktas — researcher profile on SciRah

Invite

H. Kreipe — researcher profile on SciRah

Invite

M. Untch — researcher profile on SciRah

Invite

S. Kuemmel — researcher profile on SciRah

G. von Minckwitz×10

Invite

G. von Minckwitz — researcher profile on SciRah

D. Augustin×10

Invite

D. Augustin — researcher profile on SciRah